AFL | Jotup

Gray Television Partners with Revamped Arena Football League to Bring Local Spring Football to Viewers Free Over-The-Air Starting April 27

Retrieved on:

Thursday, March 28, 2024

Storm, Georgia Force, Rapid City Marshals, Networking hardware, Partnership, AFL, NFL Network, NFL, Arena Football League, The Sundays

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Gray Television Inc. (“Gray”) (NYSE: GTN) is pleased to announce a multi-year agreement with the Arena Football League to bring Saturday arena football games over-the-air to local audiences in at least thirty-four markets across the United States.

Key Points:

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Gray Television Inc. (“Gray”) (NYSE: GTN) is pleased to announce a multi-year agreement with the Arena Football League to bring Saturday arena football games over-the-air to local audiences in at least thirty-four markets across the United States.
The first AFL games on Gray’s television stations will air on Saturday, April 27, 2024, and continue for the ten-week 2024 AFL season.
Gray’s local broadcast AFL games primarily focus on in-state teams matched to Gray’s local television station markets.
“We’re excited to bring Spring football to local audiences,” said Sandy Breland, Gray’s Chief Operating Officer.

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Retrieved on:

Tuesday, March 26, 2024

BRISBANE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.

Key Points:

Finally, we anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year.
ANX005 in GBS: First-in-class monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain.
ANX005 in GBS: Topline data from pivotal, randomized, placebo-controlled Phase 3 trial expected in the second quarter of 2024.
Cash and operating runway: Cash and cash equivalents and short-term investments were $259.7 million as of December 31, 2023.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

Tuesday, March 26, 2024

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points:

“Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on:

Sunday, April 7, 2024

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points:

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Retrieved on:

Friday, April 5, 2024

Research, Annual report, ALS, Caregiver, Patient, PP, Table, Quality of life, Insurance, Bank statement, AFL, Pharmaceutical industry

CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.

Key Points:

CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.
Research and development expenses for the years ended December 31, 2023 and 2022 were $7,588 thousand and $6,416 thousand, respectively.
General and administrative expenses for the years ended December 31, 2023 and 2022 were $5,714 thousand and $7,136 thousand, respectively.
Operating expenses for the years ended December 31, 2023 and 2022 were $13,302 thousand and $13,552 thousand, respectively.

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Retrieved on:

Wednesday, March 13, 2024

ACT, Disease, Natural history, Survival, ALS, CNM, Risk, Patient, Biomarker, EAP, Mortality, NDA, Data, FDA, AFL, Pharmaceutical industry

In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.

Key Points:

In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.
Clene plans to submit additional data to the FDA to advance the CNM-Au8 accelerated approval discussions in 2024.
In December 2023, Clene announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8.
Clene expects that its resources as of December 31, 2023, will be sufficient to fund its operations into the fourth quarter of 2024.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on:

Wednesday, March 13, 2024

Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points:

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

AFL Announces a Multi-Million-Dollar Investment and Expansion to its U.S. Fiber Optic Cable Manufacturing Operations

Retrieved on:

Thursday, March 21, 2024

Carriers and Services, Technology, Manufacturing, White House, Federal Government, Other Technology, Telecommunications, Networks, Internet, Public Policy, Government, Engineering, Hardware, Buy America Act, AFL, Multimedia, BABA, Renewable energy

AFL, an industry-leading manufacturer of fiber optic cables, connectivity and equipment, today announced an investment of over $50 million to expand its fiber optic cable manufacturing operations in South Carolina.

Key Points:

AFL, an industry-leading manufacturer of fiber optic cables, connectivity and equipment, today announced an investment of over $50 million to expand its fiber optic cable manufacturing operations in South Carolina.
This investment aligns with the Biden-Harris administration’s Infrastructure Investment and Jobs Act and Internet for All initiatives to increase broadband access in the U.S.
View the full release here: https://www.businesswire.com/news/home/20240321481515/en/
AFL Announces a Multi-Million-Dollar Investment and Expansion to its U.S.
Today’s announcement builds on AFL’s previous investment of more than $35 million in the expansion of domestic cable manufacturing to support broadband deployment and modernization of the power grid.

NSF Marks Milestones in Personal Care for Athletes

Retrieved on:

Thursday, March 21, 2024

These certifications mark two major milestones: CBDHCC is NSF’s first client in the world to comply with NSF Guideline 527, which demonstrates the product formula meets strict limits and is free of unsafe levels of impurities and adulterants; it is also the first personal care product to earn NSF Certified for Sport® certification.

Key Points:

These certifications mark two major milestones: CBDHCC is NSF’s first client in the world to comply with NSF Guideline 527, which demonstrates the product formula meets strict limits and is free of unsafe levels of impurities and adulterants; it is also the first personal care product to earn NSF Certified for Sport® certification.
"The spirit of clean athletic competition is something we all connect with,” said David Trosin, Senior Director, Global Certification at NSF.
NSF Certified for Sport® certifies dietary supplements, functional foods, cosmetics and personal care products to be free from substances banned by major sporting organizations.
Products Certified for Sport® must also be certified to either NSF/ANSI 173, NSF 229 or NSF 527 to ensure their contents match their claims.

AM Best Assigns Issue Credit Ratings to Aflac Incorporated’s New Senior Unsecured Notes

Retrieved on:

Thursday, March 14, 2024

Insurance, Professional Services, Average revenue per user, AFL, ALL, News, Credit, AM Best, Federal Home Loan Banks, Security (finance)

-- JPY 13.0 billion 1.048% due March 21, 2029

Key Points:

AM Best has assigned Long-Term Issue Credit Ratings (Long-Term IR) of “a” (Excellent) to Aflac Incorporated’s (Aflac) (Columbus, GA) [NYSE: AFL] newly issued senior unsecured notes (see detailed list below).
AM Best notes that Aflac maintained ample liquidity and strong financial flexibility at year-end 2023.
For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .